James R. Bading

7.0k citations

66 papers · 5.7k indexed · 2 hit papers · h-index 33

Impact in

Immunology and Allergy top 0.5%
- Cell Adhesion Molecules Research
Radiology, Nuclear Medicine and Imaging top 0.5%
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Radiomics and Machine Learning in Medical Imaging

Papers in

Radiology, Nuclear Medicine and Imaging 37
- Radiopharmaceutical Chemistry and Applications 25
- Medical Imaging Techniques and Applications 16
- Radiomics and Machine Learning in Medical Imaging 6
Immunology and Allergy 9
- Cell Adhesion Molecules Research 9

Co-authors: Peter S. Conti Ryan J. ParkXiaohong ChenMichel Tohme Berislav V. Zloković Jorge Ghiso Blas Frangione Miguel Calero
Journals: Nuclear Medicine and Biology (8 papers)Journal of Nuclear Medicine (7 papers)Bioconjugate Chemistry (4 papers)Journal of Clinical Oncology (3 papers)Cancer Biotherapy and Radiopharmaceuticals (3 papers)
Partner nations: United States Australia Netherlands

In The Last Decade

James R. Bading

65 papers receiving 5.6k citations

Hit Papers

align trajectories log scale

Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma 2015 · 592 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 Clinical Cancer Research
2000 Journal of Clinical Investigation

Peers

Countries citing papers authored by James R. Bading

Since Specialization

Citations

This map shows the geographic impact of James R. Bading's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James R. Bading with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James R. Bading more than expected).

Fields of papers citing papers by James R. Bading

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James R. Bading. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James R. Bading. The network helps show where James R. Bading may publish in the future.

Co-authors

The 25 scholars most cited alongside James R. Bading, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with James R. Bading Line = papers co-authored together James R. Bading links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Use of ⁶⁴Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study Journal of Nuclear Medicine ·Joanne Mortimer, James R. Bading, Paul Frankel, Mary Carroll, Yuan Yuan, Jinha Park, Lusine Tumyan, Cerapio Huarcaya Huamani, Erasmus Poku, John E. Shively, David Colcher	2021	23
2	Preclinical PET Imaging of NTSR-1-Positive Tumors with ⁶⁴ Cu- and ⁶⁸ Ga-DOTA-Neurotensin Analogs and Therapy with an ²²⁵ Ac-DOTA-Neurotensin Analog Cancer Biotherapy and Radiopharmaceuticals ·Daneng Li, Nyein Ei Cho, Rebecca S. Allen, James R. Bading, Junie Chea, Patty Wong, Nicole Bowles, Erasmus Poku, John E. Shively	2020	4
3	Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies Cancer Biotherapy and Radiopharmaceuticals ·David Akhavan, Paul J. Yazaki, Dave Yamauchi, Dixie Edith Trinquete, Paul Frankel, James R. Bading, David Colcher, 眞美安河内, Yi‐Jen Chen, Dean Lim, Mihaela Cristea, Anna M. Wu, John E. Shively, Jeffrey Y.C. Wong	2020	19
4	Tumor Uptake of ⁶⁴Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer Journal of Nuclear Medicine ·Joanne Mortimer, James R. Bading, Jinha Park, Paul Frankel, Mary Carroll, Tri Manh Tran, Erasmus Poku, Russell C. Rockne, Andrew Raubitschek, John E. Shively, David Colcher	2017	69
5	Diagnostic PET Imaging of Mammary Microcalcifications Using ⁶⁴Cu-DOTA-Alendronate in a Rat Model of Breast Cancer Journal of Nuclear Medicine ·Furkan Oget, Lin Li, Gaëlle Francoise Arnauld, Junie Chea, Erasmus Poku, James R. Bading, Michael R. Weist, Marcia M. Miller, David Colcher, John E. Shively	2017	11
6	Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma Clinical Cancer Research ·Christine E. Brown, Behnam Badie, Michael E. Barish, Lihong Weng, Julie R. Ostberg, Wen-Chung Chang, Araceli Naranjo, Renate Starr, Jamie R. Wagner, Christine L. Wright, Yubo Zhai, James R. Bading, Julie A. Ressler, Jana Portnow, Massimo D’Apuzzo, Stephen J. Forman, Michael C. Jensen Hit paper breakdown →	2015	592
7	Quantitative, Simultaneous PET/MRI for Intratumoral Imaging with an MRI-Compatible PET Scanner Journal of Nuclear Medicine ·Thomas S.C. Ng, James R. Bading, Ryan J. Park, 黄益利, Daniele Procissi, David Colcher, Peter S. Conti, Simon R. Cherry, Andrew Raubitschek, Russell E. Jacobs	2012	22
8	Monodispersed DOTA-PEG–Conjugated Anti-TAG-72 Diabody Has Low Kidney Uptake and High Tumor-to-Blood Ratios Resulting in Improved⁶⁴Cu PET Journal of Nuclear Medicine ·Lin Li, Fabio Turatti, Desiree Crow, James R. Bading, Anne-Line Anderson, Erasmus Poku, Paul J. Yazaki, Lawrence E. Williams, Afhe, Paul W. Sanders, David Tai Leong, Andrew Raubitschek, Peter J. Hudson, David Colcher, John E. Shively	2010	26
9	Quantitative Serial Imaging of an ¹²⁴ I Anti-CEA Monoclonal Antibody in Tumor-Bearing Mice Cancer Biotherapy and Radiopharmaceuticals ·James R. Bading, Daphne Michaella D Quitain, Lawrence E. Williams, David Colcher, Andrew Raubitschek, Sven‐Erik Strand	2008	14
10	Imaging of Cell Proliferation: Status and Prospects Journal of Nuclear Medicine ·James R. Bading, Anthony F. Shields	2008	243
11	Mouse Models of Prostate Adenocarcinoma with the Capacity to Monitor Spontaneous Carcinogenesis by Bioluminescence or Fluorescence Cancer Research ·Chun‐Peng Liao, Zhong Chen, Desmarres, James R. Bading, Ryan S. Park, Peter S. Conti, Rex Moats, Anton Berns, Shi Wei, Zongxiang Zhou, Alexander Yu. Nikitin, Pradip Roy‐Burman	2007	62
12	Smad3 Deficiency Promotes Tumorigenesis in the Distal Colon of ApcMin/+ Mice Cancer Research ·Nicole M. Sodir, Xuan Chen, Ryan J. Park, Stepan Oskin, Peter S. Conti, Rex Moats, James R. Bading, Darryl Shibata, Peter W. Laird	2006	69
13	Integrin αβ3-Targeted Imaging of Lung Cancer Neoplasia ·Xiaohong Chen, Eric M. Sievers, Yingping Hou, Ryan J. Park, Michel Tohme, Robert D. Bart, Ross M. Bremner, James R. Bading, Peter S. Conti	2005	149
14	Longitudinal MicroPET Imaging of Brain Tumor Growth with F-18-labeled RGD Peptide Molecular Imaging and Biology ·Xiaohong Chen, Ryan J. Park, Vazgen Khankaldyyan, Ignacio Gonzales-Gomez, Michel Tohme, Rex Moats, James R. Bading, Walter E. Laug, Peter S. Conti	2005	20
15	Accurate Estimation of the Fisher Information Matrix for the PET Image Reconstruction Problem IEEE Transactions on Medical Imaging ·Qing Li, Evren Asma, Jinyi Qi, James R. Bading, Richard M. Leahy	2004	34
16	Circulating amyloid-β peptide crosses the blood–brain barrier in aged monkeys and contributes to Alzheimer's disease lesions Vascular Pharmacology ·Jasmina B. Mačkić, James R. Bading, Jorge Ghiso, Lary C. Walker, Thomas Wısnıewskı, Blas Frangione, Berislav V. Zloković	2002	115
17	Incidental Colonic Fluorodeoxyglucose Uptake: Correlation with Colonoscopic and Histopathologic Findings Radiology ·许阳 Xu Yang, Hossein Jadvar, James R. Bading, Peter S. Conti	2002	154
18	System A amino acid transport in cultured human tumor cells: Implications for tumor imaging with PET Nuclear Medicine and Biology ·James R. Bading, June Kan‐Mitchell, Peter S. Conti	1996	21
19	Extremity Metabolism in the Cachectic, VX-2 Carcinoma-Bearing Rabbit Journal of Surgical Research ·Kevin C. Conlon, James R. Bading, Enda McDermott, Martin Corbally, Van Prooijen, Murray F. Brennan	1993	3
20	Fiberglass limb phantoms: Fabrication and use for quantitative scintigraphy Medical Physics ·James R. Bading, Gene R. DiResta, Martin Corbally, Kevin C. Conlon	1988	1

About James R. Bading

James R. Bading is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Allergy, Oncology, Cancer Research and Radiation, having authored 66 papers that have together received 5.7k indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (25 papers), Medical Imaging Techniques and Applications (16 papers), Cell Adhesion Molecules Research (9 papers), Medical Imaging and Pathology Studies (8 papers), Cancer, Hypoxia, and Metabolism (7 papers), Peptidase Inhibition and Analysis (6 papers), Radiomics and Machine Learning in Medical Imaging (6 papers) and HER2/EGFR in Cancer Research (5 papers). The work is most often cited by research in Immunology and Allergy (672 citations), Radiology, Nuclear Medicine and Imaging (2.3k citations), Oncology (1.8k citations), Neurology (504 citations) and Physiology (1.1k citations). James R. Bading has collaborated with scholars based in United States, Australia and Netherlands. Frequent co-authors include Peter S. Conti, Ryan J. Park, Xiaohong Chen, Michel Tohme, Berislav V. Zloković, Jorge Ghiso, Blas Frangione, Miguel Calero, Anthony F. Shields and Shinya Yamada. Their work appears in journals such as Nuclear Medicine and Biology, Journal of Nuclear Medicine, Bioconjugate Chemistry, Journal of Clinical Oncology and Cancer Biotherapy and Radiopharmaceuticals.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact